ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has issued an announcement.
ImmuneOnco Biopharmaceuticals announced its annual results for 2024, highlighting significant progress in its oncology drug pipeline. The company completed patient enrollment for Phase II clinical trials of IMM01 for treating higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia, achieving promising response rates. These results have been selected for presentation at major oncology conferences, indicating potential positive impacts on the company’s industry positioning and stakeholder interests.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. operates in the biopharmaceutical industry, focusing on the development of oncology products. The company is primarily engaged in advancing its drug pipeline, with a particular emphasis on its core product, IMM01, a SIRP α-Fc Fusion Protein.
YTD Price Performance: -6.20%
Average Trading Volume: 8,355,914
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.92B
Find detailed analytics on 1541 stock on TipRanks’ Stock Analysis page.